Pemetrexed in advanced non-small cell lung cancer

被引:20
|
作者
Gridelli, Cesare [1 ]
Maione, Paolo [1 ]
Rossi, Antonio [1 ]
Bareschino, Maria Anna [1 ]
Schettino, Clorinda [1 ]
Sacco, Paola Claudia [1 ]
Zeppa, Rosario [1 ]
机构
[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy
关键词
chemotherapy; NSCLC; pemetrexed; safety; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; 1ST-LINE CHEMOTHERAPY; CARBOPLATIN; BEVACIZUMAB; PACLITAXEL; ANTIFOLATE; GEFITINIB; DOCETAXEL; LY231514;
D O I
10.1517/14740338.2011.553281
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing and the search for new active and safe drugs is warranted. The chemotherapeutic agent pemetrexed has produced, in the last years, an innovation of therapeutic algorithms of this disease, and this review is aimed at describing the role of pemetrexed in the treatment of NSCLC. Areas covered: In the present review, we discuss the mechanism of action of pemetrexed, its safety profile and the main clinical data on pemetrexed in NSCLC treatment. The reader will gain information on pemetrexed efficacy in the first-line, second-line and maintenance treatment of advanced NSCLC. Moreover, the histotype-based approach to NSCLC treatment, which is important for the selection of patients to be treated with pemetrexed, is clarified. Expert opinion: The recent introduction of pemetrexed in the first-line and maintenance treatment of advanced non-squamous NSCLC represents, in our opinion, a significant step forward in the treatment of this disease in the last 3 years. Furthermore, cisplatin plus pemetrexed has a more favorable safety profile as compared with those of pre-existing cisplatin-based regimens.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 50 条
  • [31] THE BUDGETARY IMPACT OF PEMETREXED MAINTENANCE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Klein, R.
    Lawson, A. H.
    Muehlenbein, C. E.
    Liepa, A. M.
    Wielage, R. C.
    Babineaux, S.
    Koustenis, A. G.
    VALUE IN HEALTH, 2010, 13 (03) : A28 - A28
  • [32] Pseudocellulitis in the Setting of Pemetrexed Treatment for Non-Small Cell Lung Cancer
    Nguyen, Cassidy M.
    Robertson, Jake C.
    Cardenas, Adam
    Martinez, Edgar
    Keeling, Brett H.
    Nguyen, Khang D.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2025, 52 (04) : 284 - 286
  • [33] Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
    Li, Tianhong
    Lara, Primo N., Jr.
    Mack, Philip C.
    Perez-Soler, Roman
    Gandara, David R.
    CURRENT DRUG TARGETS, 2010, 11 (01) : 85 - 94
  • [34] Pemetrexed combination therapy in the treatment of non-small cell lung cancer
    Rosell, R
    Crinó, L
    SEMINARS IN ONCOLOGY, 2002, 29 (02) : 23 - 29
  • [35] Pemetrexed-induced Typhlitis in Non-small Cell Lung Cancer
    Shvartsbeyn, Marianna
    Edelman, Martin J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) : 1188 - 1190
  • [36] Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium
    Feliciano, Josephine
    Patel, Jyoti
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 737 - 748
  • [37] RETROSPECTIVE ANALYSIS OF PEMETREXED IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Shimada, M.
    Kitazaki, T.
    Fukuda, M.
    Hashiguchi, K.
    Ogawara, D.
    Yamaguchi, H.
    Tomonaga, N.
    Soda, H.
    Nakamura, Y.
    Kohno, S.
    RESPIROLOGY, 2012, 17 : 80 - 80
  • [38] Pemetrexed A Review of its Use in the Management of Advanced Non-Squamous Non-Small Cell Lung Cancer
    Baldwin, Claudine M.
    Perry, Caroline M.
    DRUGS, 2009, 69 (16) : 2279 - 2302
  • [39] RETROSPECTIVE ANALYSIS OF PEMETREXED IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Kitazaki, Takeshi
    Ogawara, Daiki
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Shimada, Midori
    Ikeda, Takaya
    Tomonaga, Nanae
    Soda, Hiroshi
    Nakamura, Yoichi
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S489 - S489
  • [40] Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
    Lal, R.
    Hillerdal, G. N.
    Shah, R. N. H.
    Crosse, B.
    Thompson, J.
    Nicolson, M.
    Vikstrom, A.
    Potter, V. A.
    Visseren-Grul, C.
    Lorenzo, M.
    D'yachkova, Y.
    Bourayou, N.
    Summers, Y. J.
    LUNG CANCER, 2015, 89 (02) : 154 - 160